The American Journal of Managed Care

Anlotinib Plus Chemotherapy Shows Promising Results in Advanced Soft Tissue Sarcoma

Anlotinib combined with chemotherapy showed a 30.8% ORR and 82.7% DCR in advanced STS patients, indicating promising efficacy ...
The American Journal of Managed Care

France Expands BOT–BAL Immunotherapy Access for Ovarian Cancer and Soft Tissue Sarcoma

Combination therapy of botensilimab (BOT) plus balstilimab (BAL) was approved Monday as an updated national treatment protocol for patients with certain ovarian cancers and soft tissue sarcomas (STS) ...
CURE

FDA Grants Orphan Drug Designation to LP-284 for Soft Tissue Sarcoma

The FDA's orphan drug designation supports LP-284's development for soft tissue sarcomas, addressing significant unmet needs in this adult patient population. The FDA granted orphan drug designation ...
EurekAlert!

"Glowing molecule" in this first-in-human clinical trial is poised to revolutionize soft-tissue sarcoma surgery, improving cure rates

New research from Dartmouth Health and Dartmouth Cancer Center reveals a glowing molecule designed to highlight soft-tissue sarcomas during surgery, paving the way for more precise tumor removal and ...
Pharmabiz

Faron Pharma expands bexmarilimab programme in solid tumours with a randomized phase I/II BEXAR IIT in metastatic soft-tissue sarcoma

Faron Pharma expands bexmarilimab programme in solid tumours with a randomized phase I/II BEXAR IIT in metastatic soft-tissue sarcoma: Turku, Finland Thursday, January 29, 2026, 1 ...